Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
07/03/2024 11:14
March 7 (Reuters) - Panbela Therapeutics Inc PBLA.O :
* PANBELA THERAPEUTICS: ON MARCH 5, NASDAQ NOTIFIED CO
NOTICE OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD
* PANBELA THERAPEUTICS : NASDAQ DETERMINED TO DELIST CO'S
COMMON
STOCK, TRADING TO BE SUSPENDED ON MARCH 7
* PANBELA THERAPEUTICS: CO EXPECTS COMMON STOCK TO BE
ELIGIBLE FOR
QUOTATION ON OTC PINK MARKET UNDER SYMBOL, "PBLA"
Source text for Eikon: ID:n0001437749-24-006889
Further company coverage: PBLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Panbela Therapeutics
See all newsBrief: Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Brief: Nasdaq Notifies Panbela Therapeutics Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Brief: Panbela Announces Pricing of Approximately $9 Mln Public Offering
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Brief: Panbela Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants